Skip to main content
Clinical Trials/NCT06459934
NCT06459934
Recruiting
Not Applicable

Clinical Outcomes of Cardiovascular Disease: a Prospective Cohort Study

Xinjiang Medical University1 site in 1 country30,000 target enrollmentJune 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
Xinjiang Medical University
Enrollment
30000
Locations
1
Primary Endpoint
Heart failure
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Evaluate multiple examination indicators of patients at baseline, 1 year and longer, and follow up on the incidence of major cardiovascular and cerebrovascular adverse events, heart failure readmission, death, and other endpoint events.

Detailed Description

This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Mainly including coronary heart disease, cardiomyopathy, hypertension, heart failure and other diseases, multiple examination indicators are evaluated for patients at baseline, 1 year and longer periods of time. The primary endpoints for coronary heart disease are all-cause mortality, cardiogenic death, non fatal myocardial infarction, hospitalization for heart failure, and major cardiovascular adverse events. The primary endpoints for cardiomyopathy are all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular adverse events. The primary endpoints for hypertension are stroke, all-cause mortality, cardiogenic death, hospitalization for heart failure, and major cardiovascular and cerebrovascular adverse events. The primary endpoints for heart failure are all-cause mortality, cardiogenic death, readmission for heart failure, and major cardiovascular adverse events.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
December 31, 2028
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Xinjiang Medical University
Responsible Party
Principal Investigator
Principal Investigator

Xiang Xie

Director

Xinjiang Medical University

Eligibility Criteria

Inclusion Criteria

  • Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%.
  • Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and/or the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs.
  • Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure.
  • Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.
  • Able to sign informed consent form.

Exclusion Criteria

  • Age\<18 years old, or\>80 years old.
  • Patients with various malignant tumors.
  • Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit).
  • Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit).
  • Those who have participated in other clinical studies within the past three months.
  • Individuals without legal capacity or with limited legal capacity.
  • Any situation where the researcher deems it unsuitable to participate in the clinical study.

Outcomes

Primary Outcomes

Heart failure

Time Frame: 1 year.

Heart failure (HF) is defined according to the diagnostic criteria for HF. Briefly, HF was defined as typical signs and symptoms of HF (NYHA class III or IV), as well as a history of myocardial infarct (MI) or with advanced coronary artery disease including severe 3-vessel disease and chronic total occlusion or other Organic heart disease.

Stroke

Time Frame: 1 year.

Stroke was defined as a sudden onset of vertigo, numbness, aphasia, or dysarthria caused by cerebrovascular disease, including hemorrhage, embolism, thrombosis, or aneurysm rupture, and persisting for \> 24 hours

Cardiac death

Time Frame: 1 year.

Death caused by cardiac reasons.

Main adverse cardiovascular events(MACE)

Time Frame: 1 year.

The composite endpoint for hospitalization for heart failure, non fatal myocardial infarction, and cardiac death.

All cause death

Time Frame: 1 year.

Death caused by various reasons.

Secondary Outcomes

  • Main adverse cardiovascular and cerebrovascular events(MACCE)(3 years.)
  • Cardiac death(3 years.)
  • Main adverse cardiovascular events(MACE)(3 years.)
  • All cause death(3 years.)
  • Heart failure(3 years.)
  • Stroke(3 years.)

Study Sites (1)

Loading locations...

Similar Trials